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Abstract
Background: Well-differentiated neuroendocrine carcinomas are highly vascularized and may be
sensitive to drugs administered on a metronomic schedule that has shown antiangiogenic
properties. A phase II study was designed to test the activity of protracted 5-fluorouracil (5FU)
infusion plus long-acting release (LAR) octreotide in patients with neuroendocrine carcinoma.
Methods:  Twenty-nine patients with metastatic or locally advanced well-differentiated
neuroendocrine carcinoma were treated with protracted 5FU intravenous infusion (200 mg/m2
daily) plus LAR octreotide (20 mg monthly). Patients were followed for toxicity, objective
response, symptomatic and biochemical response, time to progression and survival.
Results: Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) criteria showed
partial response in 7 (24.1%), stable disease in 20 (69.0%), and disease progression in 2 patients.
Response did not significantly differ when patients were stratified by primary tumor site and
proliferative activity. A biochemical (chromogranin A) response was observed in 12/25 assessable
patients (48.0%); symptom relief was obtained in 9/15 symptomatic patients (60.0%). There was
non significant decrease in circulating vascular epithelial growth factor (VEGF) over time. Median
time to progression was 22.6 months (range, 2.7-68.5); median overall survival was not reached
yet. Toxicity was mild and manageable.
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Conclusion: Continuous/metronomic 5FU infusion plus LAR octreotide is well tolerated and
shows activity in patients with well-differentiated neuroendocrine carcinoma. The potential
synergism between metronomic chemotherapy and antiangiogenic drugs provides a rationale for
exploring this association in the future.
Trial registration: NCT00953394
Background
Well-differentiated neuroendocrine carcinomas are a
group of rare malignancies generally characterized by low
aggressiveness [1-4]. Surgery is the only curative modality.
In unresectable disease, somatostatin analogues effec-
tively reduce hormonal hypersecretion, but tumor shrink-
age is only rarely seen (0%-6% of patients) [5,6].
Because of their low proliferative activity, conventional
chemotherapy for these tumors is not recommended [7-
9]. Metronomic chemotherapy, i.e., the frequent adminis-
tration of cytotoxic drugs at low doses [10], has demon-
strated antiangiogenetic properties [11-13]. Since well-
differentiated neuroendocrine carcinomas are highly vas-
cular [14,15], there is a rationale for testing metronomic
chemotherapy in this clinical setting [16].
Five-fluorouracil (5FU) is frequently employed in the
treatment of advanced neuroendocrine carcinoma [17-
19]. The combination of protracted 5FU infusion and alfa
2b interferon has been tested in the treatment of well-dif-
ferentiated neuroendocrine carcinomas of the gastroen-
teropancreatic tract, and a disease response obtained in
more than 40% of patients [20]. Moreover, concomitant
administration of somatostatin analogues to enhance the
effect of the antiproliferative activity of 5FU has been
reported in several in vitro and in vivo preclinical studies
[21].
On these grounds, the Piemonte Region Oncology Net-
work conducted a multicenter phase II trial to assess the
activity and safety profile of a combination regimen of
protracted 5FU infusion and long-acting release (LAR)
octreotide in patients with advanced well-differentiated
neuroendocrine carcinomas. The primary study aim was
to assess response to treatment; the secondary aims were
to evaluate toxicity, biochemical and symptomatic
response, time to progression and survival.
Methods
Study population
Eligibility criteria included histological diagnosis of well-
differentiated neuroendocrine carcinoma according to the
World Health Organization (WHO) classification [1],
locally advanced or metastatic disease not amenable to
surgery with radical intent, at least one measurable target
lesion, radiological documentation of progressive disease,
somatostatin receptor scintigraphy, Eastern Cooperative
Oncology Group (ECOG) performance status grade ≤ 2,
life expectancy ≥ 12 weeks, adequate bone marrow reserve
(WBC count ≥ 3.5 × 109/L, platelets ≥ 100 × 109/L, hemo-
globin ≥ 10 g/dL), adequate hepatic and renal function
(hepatic enzymes and bilirubin < 2 × upper limit of nor-
mal, serum creatinine < 1.4 mg/dl). Exclusion criteria
were non-malignant systemic disease or conditions that
precluded patients from receiving the study therapy, sec-
ond primary malignancies, and previous systemic antine-
oplastic treatment including somatostatin analogues.
Diagnostic work-up included physical examination,
screening chemistry, circulating chromogranin A (CgA),
abdominal, chest and pelvis computed tomography (CT),
and somatostatin receptor scintigraphy. The study was
approved by the local ethic committee of each participat-
ing center. Written informed consent was obtained from
all patients before starting treatment.
Histology and immunohistochemical analysis
The histological diagnoses performed at each center were
centrally reviewed by two experienced pathologists using
the proposed morphological criteria for well-differenti-
ated neuroendocrine carcinoma [1]. In addition, immu-
nohistochemical analysis of the Ki-67 proliferation index
(DakoCytomation, Glostrup, Denmark, clone MIB-1,
diluted 1/300), type 2 somatostatin receptor expression
(BioTrend, Cologne, Germany, code SS-800, diluted 1/
3000) and VEGF marker levels (NeoMarkers, Fremont,
CA, USA, polyclonal, diluted 1/250) was performed.
Treatment plan and toxicity assessment
LAR octreotide acetate at a dose of 20 mg was adminis-
tered intramuscularly every 4 weeks. The first administra-
tion was matched to an induction treatment of octreotide
(0.1 mg subcutaneous every 8 h) for 14 days; 5FU was
given as a protracted continuous infusion without inter-
ruption at a daily dose of 200 mg/m2 of body-surface area
through an elastomeric pump connected to a central
venous access.
5FU treatment was planned to be administered for 6
months, however, prolonged 5FU administration beyond
6 months was permitted. LAR octreotide administration
was continued until disease progression.BMC Cancer 2009, 9:388 http://www.biomedcentral.com/1471-2407/9/388
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Toxicity was assessed according to National Cancer Insti-
tute Common Toxicity Criteria (NCI CTC) [22].
5FU dose modifications were performed as follows: if
WBC count was < 2500/mL and/or platelet count <
100,000/mL, 5FU was delayed for 1 week. If the blood
count did not recover, then 5FU was delayed for a further
week and the dose reduced by 25%. In the event of severe
plantar-palmar erythema with blistering and desquama-
tion, 5FU was interrupted until healing had occurred. In
the event of persistent diarrhea and/or grade 2 mucositis,
5FU was discontinued for 1 week. If grade 3/4 diarrhea
and mucositis occurred, 5FU was withdrawn until recov-
ery then resumed at a dose reduced by 25%.
Response evaluation
A CT scan was performed every 12 weeks after initiation of
treatment. Disease response was evaluated according to
RECIST criteria [23].
Symptomatic patients were asked to keep a diary where
they reported frequency and duration of disease-related
symptoms. CR was defined as the complete relief of all
symptoms and PR as a reduction of at least 50% in both
the frequency and intensity of symptoms.
Circulating CgA was measured every 3 months using a
commercially available assay (DAKO ELISA, DAKO A/S,
Glostrup, Denmark). A decline in CgA levels was consid-
ered a biochemical response and defined as either a CR if
the tumor marker level returned to normal or as a PR if
tumor marker levels decreased by 50% or more. An
increase of more than 25% in CgA levels was defined as
biochemical progression.
Circulating VEGF levels were retrospectively assessed
using a sandwich enzyme immunoassay technique with a
monoclonal antibody specific for VEGF (R&D System
Europe, Abingdon, UK) in plasma samples collected at
baseline and after 3 and 6 months in 11 patients, all
recruited at the study coordinating center (San Luigi Hos-
pital, Orbassano, Torino).
Statistical analysis
The primary end point of the study was the response rate.
A Simon two-stage design [24] was used to test the null
hypothesis that the true objective response rate was <
10%. The upper limit of first-step drug rejection was 1
response (CR or PR) in the first 10 consecutive patients;
the upper limit of second-step rejection was 5 responses in
29 consecutively enrolled patients. Time to progression
(TTP) and overall survival (OS) were assessed using the
Kaplan-Meier product limit estimate method. The rates of
TTP and OS were measured from the date of treatment
start to the date of progression and the date of last follow-
up or death, respectively. A Cox proportional-hazards
regression analysis was used to assess in multivariate anal-
ysis the prognostic role of mitosis count and Ki67 expres-
sion. Changes in VEGF levels over time were assessed by
the Friedman analysis of variance for non parametric
matched paired data. P values < 0.05 were considered sta-
tistically significant. Statistical analyses were performed
using the Statistica/PC software program (Statsoft, Tulsa
OK, USA).
Results
Patient characteristics
Twenty-nine patients with locally advanced or metastatic
disease with radiological documentation of progressive
disease were entered into the study at the seven participat-
ing centers from 2004 to 2006. The baseline patient char-
acteristics are depicted in Table 1. No patients had
received any previous systemic antineoplastic treatment
including somatostatin analogues. None had received
radionuclide therapy before entry into the study.
A diagnosis of well-differentiated neuroendocrine carci-
noma was confirmed in 28 patients by central histological
review. One patient had a poorly differentiated carcinoma
and was therefore ineligible. However, according to the
intent-to-treat principle, this patient was included in the
analyses.
Treatment and toxicity
5FU treatment was administered for a median duration of
6 months (range, 2-9). Twenty-three patients (79.3%)
completed the scheduled 6-month 5FU treatment. Six
patients interrupted earlier because of disease progression
(2 cases), patient decision (1 case), radionuclide therapy
(2 cases), and surgical debulking to control an insulinoma
syndrome (1 case). Associated side effects were mild
(Table 2). No hematologic grade III-IV events were
recorded. Grade II-III mucositis and diarrhea occurred in
3 patients (10.3%). Two patients (6.9%) developed grade
III hand-foot syndrome. 5FU administration was delayed
for at least 1 week in 8 patients (27.6%) and for 2 weeks
in 3 patients (10.3%). The reasons for the delayed course
were hematological in 1 patient and non-hematological
(mucositis, diarrhea, cutaneous) in the other 10 cases.
5FU infusion was reduced by 75% in 2 patients due to old
age and grade III diarrhea and reduced by 50% in 1
patient due to grade III mucositis.
Treatment activity
Seven patients attained a PR (24.1%), 20 SD (69.0%), and
2 (6.9%) progressed (Table 3). Disease responses were
observed in patients with liver (5 patients) and lymph
node metastasis (2 patients).BMC Cancer 2009, 9:388 http://www.biomedcentral.com/1471-2407/9/388
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Table 1: Patient characteristics
Patients N = 29
Median age (range) - yrs 59 (26 -- 80)
Gender -- no. (%)
Male (%) 15 (52.0)
Female (%) 14 (48.0)
ECOG performance status -- no. (%)
0 11 (37.9)
1 17 (58.6)
2 1 (3.5)
Primary tumor site -- no. (%)
Pancreas 13 (44.8)
Functioning 5 (17.2)
Unknown 7 (24.2)
Small bowel 7 (24.2)
Appendix 1 (3.4)
Colon 1 (3.4)
Tumor Stage -- no. (%)
Locally advanced/metastatic 2/27
Site of metastases -- no. (%)
< 2 sites 13 (44.8)
≥ 2 sites 16 (55.2)
Prior therapies -- no. (%)
Surgery 9 (31.0)
Progressive disease 29 (100)
Baseline symptoms -- no. (%)
Diarrhea 6 (20.6)
Flushing 4 (13.8)
Carcinoid syndrome 4 (13.8)
Hypoglycemia 2 (6.9)
Others 10 (34.5)
Circulating chromogranin A levels (U/L) - no. (%)
Normal levels 4 (13.8)
Supranormal levels 25 (86.2)
Histological tumor characteristics -- no. (%)
SST2
1+ 2 (9.1)
2+ 8 (36.4)
3+ 12 (54.5)
missing 7
Mitosis (per square millimeter)
< 2 17 (68.0)
2 -- 20 7 (28.0)
> 20 1 (4.0)
missing 4
Ki67
≤ 2% 11 (42.3)
3 -- 10% 13 (50.0)
> 10% 2 (7.7)
missing 3
VEGF
0 3 (15.8)
1 4 (21.1)
2 7 (36.8)
3 5 (26.8)
missing 10
SST2 = somatostatin receptor type 2
VEGF = vascular endothelial growth factorBMC Cancer 2009, 9:388 http://www.biomedcentral.com/1471-2407/9/388
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Biochemical and symptomatic response was obtained in
48% and 60% of patients, respectively. After medical
treatment, surgery was carried out in 3 patients: 1 with a
PR and 2 with SD (minimal tumor shrinkage < 20%). One
patient was operated for surgical removal of a primary
pancreatic tumor and chemoembolization of liver metas-
tases; 1 patient underwent right hemicolectomy plus
intraoperative radiofrequency ablation of liver metastases,
1 patient underwent radical excision of a primary pancre-
atic tumor and liver metastases. Disease response did not
change when the patients were stratified by primary dis-
ease site, mitotic count and Ki67.
In the 11 patients with circulating VEGF assessed before
and after treatment, there was a non significant trend of
progressive marker reduction over time (mean VEGF lev-
els 147, 96, and 67 pg/ml at baseline, 3 and 6 months,
respectively, P = 0.33). VEGF decreased > 50% from base-
line in 5 patients, between 25 and 50% in 2, < 25% in 2,
and increased > 25% in 2.
Predictors of patient outcome
At the last follow-up evaluation, 16 (55.2%) patients
showed disease progression and 7 (24.1%) had died; the
median duration of follow-up was 51 months.
The median TTP of all 29 patients was 22.6 months
(range, 2.7-68.5), while the median OS was not reached.
After 2 years, 48% of patients were free from progression
and 82% were alive. In the univariate analysis, Ki67
immunostaining at a cutoff value ≤ 2% and mitotic count
at a cutoff value < 2% were predictors of either TTP (P <
0.005 and P < 0.003) or OS (P = 0.06 and P = 0.004) (Fig-
ure 1), while age, sex, patient performance status, primary
disease site and VEGF expression were not. In the multi-
variate analysis, Ki67 (continuous variable) but not
mitotic count was an independent predictor of either dis-
ease recurrence (hazard ratio [HR] 1.03, 95% confidence
interval [CI] 1.00-1.06; P = 0.05) or death (HR 1.04, 95%
CI 1.00-1.08; P < 0.04). Of the 3 patients who underwent
surgery after treatment, only 1 patient progressed after
20.0 months. The remaining 2 patients were alive and free
from progression after 29.7 and 35.1 months, respec-
tively.
Discussion
In this multicenter phase II trial, protracted 5-fluorouracil
(5FU) infusion administered in combination with LAR
octreotide was an active regimen in the upfront treatment
of advanced neuroendocrine carcinomas. This regimen
was associated with an overall objective response rate of
24%, a biochemical response rate of 48%, and a sympto-
matic response rate of 60%. To our knowledge, this is the
first trial to test the activity of the combination of octre-
otide and a chemotherapy drug in somatostatin-naïve
patients. Due to the rarity of neuroendocrine tumors, this
trial was not randomized and this represents a limitation.
Nonetheless, the objective response rate obtained here
seems to be higher than that expected with somatostatin
alone (0-6%) [4,8,25]. The recently presented results of
the first randomized study testing the efficacy of octre-
otide versus placebo in metastatic well-differentiated neu-
roendocrine carcinoma showed that octreotide was
superior to placebo in prolonging time to progression,
despite a comparable response rate [26]. These data fur-
ther confirm that the antineoplastic activity of somatasta-
tin analogues is not due to tumor shrinkage but rather to
Table 2: Treatment-related toxicity.
Higher grade WHO toxicity N = 29
No. (%)
N = 29
No. (%)
N = 29
No. (%)
123
Anemia -- 2 (6.9) --
Thrombocytopenia 1 (3.4) -- --
Neutropenia 2 (6.9) 2 (6.9) --
Asthenia 9 (31.0) 2 (6.9) --
Nausea-vomiting 7 (24.1) 1 (3.4) --
Diarrhea 16 (55.1) 2 (6.9) 1(3.4)
Hand-foot syndrome 4 (13.8) 4 (13.8) 2 (6.9)
Mucositis 4 (13.8) 2 (6.9) 1 (3.4)
Table 3: Response to treatment
Clinical response
(RECIST)
N = 29
No. (%)
Biochemical response (Chromogranin A)
N = 25
No. (%)
Symptomatic response
N = 15
No. (%)
Progression 2 (6.9) 2 (8.0)
No change 20 (69.0) 11 (44.0) 6 (40.0)
Partial response 7 (24.1) 8 (32.0) 6 (40.0)
Complete response - 4 (16.0) 3 (20.0)
Overall response 7 (24.1)
(95% CI 8.3-39.9)
12 (48.0)
(95% CI 28.0-68.0)
9 (60.0)
RECIST = Response Evaluation Criteria in Solid TumorsBMC Cancer 2009, 9:388 http://www.biomedcentral.com/1471-2407/9/388
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a prolonging of disease stabilization. The potentiality of
continuous 5FU in inducing tumor shrinkage could
improve the efficacy of systemic treatment, a finding that
needs to be assessed in a randomized study.
Due to the potential dedifferentiation of neuroendocrine
carcinomas as a consequence of progression, it is expected
that response to treatment in metastatic sites may differ
from that of primary lesions. Our series was homogene-
ous in this respect, since 27 out of 29 patients had meta-
static disease. Tumor shrinkage (partial response or
minimal response) obtained by our regimen made sur-
gery for residual disease (with/without liver chemoembol-
ization or liver radiofrequency ablation) feasible in 3
patients. Surgery for residual disease seemed to be effica-
cious, since 2 patients were disease free at the last follow-
up examination after 27 and 35 months, respectively.
In order to verify study population homogeneity, the
tumor samples were centrally reviewed by two patholo-
gists. Central review also allowed the pathologists to
assess the biological prognostic parameters. Significant
outcome predictors were mitotic count and Ki67 prolifer-
ation index, both parameters being reciprocally corre-
lated. Only Ki67, however, maintained an independent
prognostic role in the multivariate analysis, confirming
the importance of assessing this marker in these tumors
[27,28]. Ki67 is also an essential parameter in the pro-
posed grading system for foregut neuroendocrine tumors
of the stomach, duodenum, and pancreas [29]. The pro-
posed cutoff of 2% to discriminate G1 from G2 carcino-
mas was associated with better outcome, confirming a
recent report [30]. Ki67 is also used as predictive marker
of treatment response in clinical decision-making algo-
rithms [7,31]. It has been suggested that neuroendocrine
Time to progression (1a and 1b) and overall survival (1c and 1d) according to Ki67 expression at the cutoff of 2% positive cells  and mitosis count Figure 1
Time to progression (1a and 1b) and overall survival (1c and 1d) according to Ki67 expression at the cutoff of 
2% positive cells and mitosis count.
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carcinomas with high Ki67 expression may be potentially
sensitive to conventional chemotherapy, whereas tumors
with lower Ki67 expression may not [31]. This trend was
confirmed in our series but failed to attain statistical sig-
nificance.
It has been suggested that metronomic chemotherapy has
antiangiogenetic activity [10]. The activity of metronomic
chemotherapy in reducing circulating VEGF levels was
observed in a previous study in patients with advanced
breast cancer [32]. In the present study, plasma VEGF lev-
els monitored every 3 months in 11 patients showed a
stepwise reduction over time that failed to attain statistical
significance due to the small sample size. On an individ-
ual basis, however, 7 patients were noted to have a
decrease in VEGF and only 2 an increase. Taken together,
these data evince an antiangiogenic effect of continuous
5FU plus octreotide treatment.
In a recent Italian multicenter study, a combination of
oxaliplatin and metronomic capecitabine (an oral 5FU
analogue) was administered to 40 patients with malig-
nant neuroendocrine tumors. Interestingly, a disease
response was observed in 23% of patients with high-grade
and in 30% of those with low-grade neuroendocrine
tumors, respectively [33]. The introduction of metro-
nomic capecitabine could account for the high response
rate obtained in this well-differentiated subset.
Continuous 5FU infusion in this patient subset was well
tolerated as most toxicities observed were mild (grade I or
II). As expected, dose-limiting toxicities were non hema-
tolological (mucositis, diarrhea, hand-foot syndrome)
and delayed treatment in 40% of patients.
Conclusion
The combination of 5FU continuous infusion and LAR
octreotide is an active regimen in the treatment of meta-
static well-differentiated neuroendocrine carcinomas and
may have antiangiogenic activity. The potential synergism
between metronomic chemotherapy and antiangiogenic
drugs provides a rationale for exploring this association in
the future. Moreover, capecitabine is an orally available
5FU derivative found to have the same efficacy as contin-
uous 5FU infusion in patients with advanced colon carci-
noma. Capecitabine administered on a metronomic
schedule instead of 5FU infusion should be tested in
patients with advanced neuroendocrine carcinoma, thus
obviating the need for an implantable central venous
access.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
BMP and BA were critically involved in the study design,
statistical analysis, and drafting of the manuscript. DL and
BO conceived of the study, participated in designing the
study and assisted in drafting the manuscript. VM and PM
carried out the immunohistochemical analysis and the
central histological review. CF, BN, BS, PD, FB, AO, CL
participated in primer selection, attended to patients, and
revised the methods section of the manuscript. FA and ME
were involved in data collection. All authors have read
and approved the final manuscript.
Acknowledgements
This study was supported by a grant from the MIUR (Ministero dell'Istruz-
ione, dell'Università e della Ricerca)
References
1. Solcia E, Kloppel G, Sobhin LH: Histological typing of endocrine
tumours.  Springer-Verlag: New York; 2000. 
2. Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W,
Riecken EO, Wiedenmann B: International Lanreotide and
Interferon Alfa Study Group. Prospective, randomized, mul-
ticenter trial on the antiproliferative effect of lanreotide,
interferon alfa, and their combination for therapy of meta-
static neuroendocrine gastroenteropancreatic tumors--the
International Lanreotide and Interferon Alfa Study Group.  J
Clin Oncol 2003, 21:2689-2696.
3. Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carci-
noid tumors.  Cancer 2005, 5,97(4):934-59.
4. Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G,
Ruszniewski P, Woltering EA, Wiedenmann B: Consensus report
on the use of somatostatin analogs for the management of
neuroendocrine tumors of the gastroenteropancreatic sys-
tem.  Ann Oncol 2004, 15:966-973.
5. Hejna M, Schmidinger M, Raderer M: The clinical role of somato-
statin analogues as antineoplastic agents: much ado about
nothing?  Ann Oncol 2000, 13:653-668.
6. Oberg K: Neuroendocrine gastrointestinal tumors - a con-
densed overview of diagnosis and treatment.  Ann Oncol 1999,
10(S2):S3-8.
7. Oberg K: Neuroendocrine tumors of the gastrointestinal
tract: recent advances in molecular genetics, diagnosis, and
treatment.  Curr Opin Oncol 2005, 17:386-391.
8. Pavel ME, Baum U, Hahn EG, Hensen J: Doxorubicin and strepto-
zotocin after failed biotherapy of neuroendocrine tumors.
Int J Gastrointest Cancer 2005, 35:179-185.
9. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG: Phase II/III
study of doxorubicin with fluorouracil compared with strep-
tozocin with fluorouracil or dacarbazine in the treatment of
advanced carcinoid tumors: Eastern Cooperative Oncology
Group study E1281.  J Clin Oncol 2005, 22:4897-4904.
10. Kerbel RS, Kamen BA: The anti-angiogenic basis of metro-
nomic chemotherapy.  Nat Rev Cancer 2004, 7,4(6):423-36.
11. Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, Pellegrino
A, Dammacco F: Antiangiogenesis is produced by non toxic
doses of vinblastine.  Blood 1999, 94:4143-4155.
12. Rozados VR, Sànchez AM, Gervasoni SI, Berra HH, Matar P, Graciela
Scharovsky O: Metronomic therapy with cyclophosphamide
induces rat lymphoma and sarcoma regression and is devoid
of toxicity.  Ann Oncol 2004, 15:1543-1550.
13. Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S, Allevi
G, Aguggini S, Bodini G, Milani M, Dionisio R, Bernardi C, Montruccoli
A, Bruzzi P, Harris AL, Dogliotti L, Berruti A: Randomized phase
II trial of letrozole and letrozole plus low-dose metronomic
oral cyclophosphamide as primary systemic treatment in
elderly breast cancer patients.  J Clin Oncol 2006, 24(22):3623-8.
14. Couvelard A, O'Toole D, Turley H, Leek R, Sauvanet A, Degott C,
Ruszniewski P, Belghiti J, Harris AL, Gatter K, Pezzella F: Microvas-
cular density and hypoxia-inducible factor pathway in pan-
creatic endocrine tumours: negative correlation ofPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2009, 9:388 http://www.biomedcentral.com/1471-2407/9/388
Page 8 of 8
(page number not for citation purposes)
microvascular density and VEGF expression with tumour
progression.  Br J Cancer 2005, 92:94-101.
15. Phan AT, Wang L, Xie K, Zhang J, Rashid A, Evans D, Vauthey J,
Abdalla E, Abbruzzese JL, Yao JC: Association of VEGF expres-
sion with poor prognosis among patients with low-grade
neuroendocrine carcinoma.  J Clin Oncol 2006. ASCO Annual
Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), abs
4091.
16. Kulke MH, Stuart K, Earle C, Bhargava P, Clark JW, Enzinger PC, Mey-
erhardt J, Attawia M, Lawrence C, Fuchs CS: A phase II study of
temozolomide and bevacizumab in patients with advanced
neuroendocrine tumors.  J Clin Oncol 2006. ASCO Annual Meeting
Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), abs 4044.
17. Moertel C, Lefkopoulo M, Lipsitz S, Hahn R, Klaassen D: Streptozo-
cin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin
in the treatment of advanced islet-cell carcinoma.  N Engl J
Med 1992, 326:519-523.
18. Hughes MJ, Kerr DJ, Cassidy J, Soukop M, McGregor K, Blackburn N,
Yosef H, Kaye SB: A pilot study of combination therapy with
interferon-α-2a and 5-fluorouracil in metastatic carcinoid
and malignant endocrine pancreatic tumours.  Ann Oncol 1996,
7:208-210.
19. Papamichael D, Seymour MT, Penson RT, Wilson P, Gallagher CJ,
Besser GM, Slevin ML: Double modulation of 5-fluorouracil with
Interferon alpha-2a and high-dose leucovorin in advanced
neuroendocrine tumours.  Eur J Cancer 1998, 34(13):2133-2134.
20. Andreyev HJN, Scott-Mackie P, Cunningham D, Nicolson V, Norman
AR, Badve SS, Iveson A, Nicolson MC: Phase II study of continu-
ous infusion fluorouracil and interferon alfa-2b in the pallia-
tion of malignant neuroendocrine tumors.  J Clin Oncol 1995,
13:1486-1492.
21. Weckbecker G, Raulf F, Tolcsvai L, Bruns C: Potentiation of the
anti-proliferative effects of anti-cancer drugs by octreotide
in vitro and in vivo.  Digestion 1996, 57(S1):22-8.
22. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer
C, Murphy B, Cumberlin R, Coleman CN, Rubin P: CTCAE v3.0:
development of a comprehensive grading system for the
adverse effects of cancer treatment.  Semin Radiat Oncol 2003,
13:176-181.
23. Therasse P, Arbuck SG, Eisenhauer EA, Wander J, Kaplan RS, Rubin-
stein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC,
Gwyther SG: New guidelines to evaluate the response to
treatment in solid tumors. European Organization for
Research and Treatment of Cancer, National Cancer Insti-
tute of Canada.  J Natl Cancer Inst 2000, 92:205-216.
24. Simon R: Optimal two-stage designs for phase II clinical trials.
Control Clin Trials 1989, 10:1-10.
25. Arnold R, Simon B, Wied M: Treatment of neuroendocrine GEP
tumours with somatostatin analogues. A review.  Digestion
2000, 62(S1):84-91.
26. Arnold R, Muller H, Schade-Brittinger C, Rinke A, Klose K, Barth P,
Wied M, Mayer C, Aminossadati B, PROMID study group: Placebo-
controlled, double-blind, prospective, randomized study of
the effect of octreotide LAR in the control of tumor growth
in patients with metastatic neuroendoccrine midgut tumors:
A report from the PROMID study group.  J Clin Oncol 2009,
27:15S.
27. Aparicio T, Ducreux M, Baudin E, Sabourin JC, De Baere T, Mitry E,
Schlumberger M, Rougier P: Antitumour activity of somatosta-
tin analogues in progressive metastatic neuroendocrine
tumours.  Eur J Cancer 2001, 37:1014-1019.
28. Butturini G, Bettini R, Missiaglia E, Mantovani W, Dalai I, Capelli P,
Ferdeghini M, Pederzoli P, Scarpa A, Falconi M: Predictive factors
of efficacy of the somatostatin analogue octreotide as first
line therapy for advanced pancreatic endocrine carcinoma.
Endocr Relat Cancer 2006, 13:1213-1221.
29. Rindi G, Kloppel G, Ahlmann H, Caplin M, Couvelard A, de Herder
WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Körner M,
Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY,
Wiedenmann B, all other Frascati Consensus Conference partici-
pants; European Neuroendocrine Tumor Society (ENETS): TNM
staging of foregut (neuro)endocrine tumors: a consensus
proposal including a grading system.  Virchows Arch 2006,
449:395-401.
30. Pape UF, Jann H, Müller-Nordhorn J, Bockelbrink A, Berndt U, Willich
SN, Koch M, Röcken C, Rindi G, Wiedenmann B: Prognostic rele-
vance of a novel TNM classification system for upper gastro-
enteropancreatic neuroendocrine tumors.  Cancer 2008,
113:256-65.
31. Oberg K: Management of neuroendocrine tumors.  American
Society of Clinical Oncology (ASCO) 2002 Educational Book, 38th Annual
Meeting, J Clin Oncol 2008:401-405.
32. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nolè F, Peruz-
zotti G, Robertson C, Orlando L, Cinieri S, de BF, Viale G, Goldhirsch
A:  Low-dose oral methotrexate and cyclophosphamide in
metastatic breast cancer: Antitumor activity and correla-
tion with vascular growth factor levels.  Ann Oncol 2002,
13:73-80.
33. Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L,
Martinetti A, Platania M, Verzoni E, Formisano B, Bajetta R: Are
capecitabine and oxaliplatin (XELOX) suitable treatments
for progressing low-grade and high-grade neuroendocrine
tumours?  Cancer Chemother Pharmacol 2007, 59:637-642.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/9/388/pre
pub